中华皮肤科杂志 ›› 2024, Vol. 57 ›› Issue (2): 97-108.doi: 10.35541/cjd.20230358
中国医师协会皮肤科医师分会 中华医学会皮肤性病学分会 中国医疗保健国际交流促进会皮肤医学分会 疑难重症及罕见病国家重点实验室 国家皮肤与免疫疾病临床医学研究中心
收稿日期:2023-06-20
修回日期:2023-12-27
发布日期:2024-02-01
通讯作者:
晋红中；高兴华
E-mail:jinhongzhong@263.net; gaobarry@ hotmail.com
基金资助:China Dermatologist Association; Chinese Society of Dermatology; Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care; State Key Laboratory of Complex Severe and Rare Diseases; National Clinical Research Center for Dermatologic and Immunologic Diseases
Received:2023-06-20
Revised:2023-12-27
Published:2024-02-01
Contact:
Jin Hongzhong; Gao Xinghua
E-mail:jinhongzhong@263.net; gaobarry@ hotmail.com
Supported by:摘要： 【摘要】 特应性皮炎是一种常见的慢性复发性炎症性皮肤病，既往治疗药物包括外用糖皮质激素、外用钙调磷酸酶抑制剂、口服抗组胺药、系统性免疫抑制剂及糖皮质激素等。近年来，生物制剂及多种小分子药物陆续获批用于本病的治疗。中国医师协会皮肤科医师分会、中华医学会皮肤性病学分会、中国医疗保健国际交流促进会皮肤医学分会、疑难重症及罕见病国家重点实验室和国家皮肤与免疫疾病临床医学研究中心组织专家，基于近年特应性皮炎研究进展及国内外指南/共识，结合专家临床经验，针对特应性皮炎治疗药物的临床应用策略、不良反应监测及管理、特殊人群用药管理等内容形成特应性皮炎治疗药物应用管理专家共识。
中国医师协会皮肤科医师分会 中华医学会皮肤性病学分会 中国医疗保健国际交流促进会皮肤医学分会 疑难重症及罕见病国家重点实验室 国家皮肤与免疫疾病临床医学研究中心. 特应性皮炎治疗药物应用管理专家共识（2024版）[J]. 中华皮肤科杂志, 2024,57(2):97-108. doi:10.35541/cjd.20230358
China Dermatologist Association, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases. Expert consensus on the application and management of therapeutic drugs for atopic dermatitis （2024）[J]. Chinese Journal of Dermatology, 2024, 57(2): 97-108.doi:10.35541/cjd.20230358
| ［1］ | Yamamura K, Nakahara T. The dawn of a New Era in atopic dermatitis treatment［J］. J Clin Med, 2022,11（20）:6145. doi: 10.3390/jcm11206145. |
| ［2］ | 中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南（2020版）［J］. 中华皮肤科杂志, 2020,53（2）:81⁃88. doi: 10.35541/cjd.20191000. |
| ［3］ | Williams HC. Established corticosteroid creams should be applied only once daily in patients with atopic eczema［J］. BMJ, 2007,334（7606）:1272. doi: 10.1136/bmj.39195.636319.80. |
| ［4］ | Saeki H, Ohya Y, Furuta J, et al. English version of clinical practice guidelines for the management of atopic dermatitis 2021［J］. J Dermatol, 2022,49（10）:e315⁃e375. doi: 10.1111/1346⁃8138.16527. |
| ［5］ | Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies［J］. J Am Acad Dermatol, 2014,71（1）:116⁃132. doi: 10.1016/j.jaad. 2014.03.023. |
| ［6］ | Butala S, Paller AS. Optimizing topical management of atopic dermatitis［J］. Ann Allergy Asthma Immunol, 2022,128（5）:488⁃504. doi: 10.1016/j.anai.2022.03.004. |
| ［7］ | Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids［J］. J Am Acad Dermatol, 2006,54（1）:1⁃15; quiz 16⁃18. doi: 10.1016/j.jaad.2005.01.010. |
| ［8］ | Wollenberg A, Kinberger M, Arents B, et al. European guideline （EuroGuiDerm） on atopic eczema ⁃ partⅡ: non⁃systemic treatments and treatment recommendations for special AE patient populations［J］. J Eur Acad Dermatol Venereol, 2022,36（11）:1904⁃1926. doi: 10.1111/jdv.18429. |
| ［9］ | Chi CC, Kirtschig G, Aberer W, et al. Updated evidence⁃based （S2e） European Dermatology Forum guideline on topical corticosteroids in pregnancy［J］. J Eur Acad Dermatol Venereol, 2017,31（5）:761⁃773. doi: 10.1111/jdv.14101. |
| ［10］ | Chi CC, Wang SH, Mayon⁃White R, et al. Pregnancy outcomes after maternal exposure to topical corticosteroids: a UK population⁃based cohort study［J］. JAMA Dermatol, 2013,149（11）:1274⁃1280. doi: 10.1001/jamadermatol.2013.5768. |
| ［11］ | Sathishkumar D, Moss C. Topical therapy in atopic dermatitis in children［J］. Indian J Dermatol, 2016,61（6）:656⁃661. doi: 10.4103/0019⁃5154.193677. |
| ［12］ | Howell AN, Ghamrawi RI, Strowd LC, et al. Pharmacological management of atopic dermatitis in the elderly［J］. Expert Opin Pharmacother, 2020,21（7）:761⁃771. doi: 10.1080/14656566.2020. 1729738. |
| ［13］ | Remitz A, De Pità O, Mota A, et al. Position statement: topical calcineurin inhibitors in atopic dermatitis［J］. J Eur Acad Dermatol Venereol, 2018,32（12）:2074⁃2082. doi: 10.1111/jdv. 15272. |
| ［14］ | Lam M, Zhu JW, Tadrous M, et al. Association between topical calcineurin inhibitor use and risk of cancer, including lymphoma, keratinocyte carcinoma, and melanoma: a systematic review and meta⁃analysis［J］. JAMA Dermatol, 2021,157（5）:549⁃558. doi: 10.1001/jamadermatol.2021.0345. |
| ［15］ | Paller AS, Fölster⁃Holst R, Chen SC, et al. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis［J］. J Am Acad Dermatol, 2020,83（2）:375⁃381. doi: 10.1016/j.jaad.2020.03.075. |
| ［16］ | Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period［J］. J Eur Acad Dermatol Venereol, 2019,33（9）:1644⁃1659. doi: 10.1111/jdv.15709. |
| ［17］ | Salava A, Perälä M, Pelkonen A, et al. Safety of tacrolimus 0.03% and 0.1% ointments in young children with atopic dermatitis: a 36⁃month follow⁃up study［J］. Clin Exp Dermatol, 2022,47（5）:889⁃902. doi: 10.1111/ced.15024. |
| ［18］ | Zane LT, Hughes MH, Shakib S. Tolerability of crisaborole ointment for application on sensitive skin areas: a randomized, double⁃blind, vehicle⁃controlled study in healthy volunteers［J］. Am J Clin Dermatol, 2016,17（5）:519⁃526. doi: 10.1007/s40257⁃016⁃0204⁃6. |
| ［19］ | Yang H, Wang J, Zhang X, et al. Application of topical phosphodiesterase 4 inhibitors in mild to moderate atopic dermatitis: a systematic review and meta⁃analysis［J］. JAMA Dermatol, 2019,155（5）:585⁃593. doi: 10.1001/jamadermatol.2019. 0008. |
| ［20］ | McDowell L, Olin B. Crisaborole: a novel nonsteroidal topical treatment for atopic dermatitis［J］. J Pharm Technol, 2019,35（4）:172⁃178. doi: 10.1177/8755122519844507. |
| ［21］ | Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double⁃blind, vehicle⁃controlled study and a subsequent open⁃label, long⁃term study［J］. J Am Acad Dermatol, 2021,85（4）:854⁃862. doi: 10.1016/j.jaad.2021.06.014. |
| ［22］ | Hur MS, Choe YB, Ahn KJ, et al. Synergistic effect of H1⁃antihistamines on topical corticosteroids for pruritus in atopic dermatitis: a systematic review and meta⁃analysis［J］. Ann Dermatol, 2019,31（4）:420⁃425. doi: 10.5021/ad.2019.31.4.420. |
| ［23］ | Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: partⅠ. Pregnancy［J］. J Am Acad Dermatol, 2014,70（3）:401.e1⁃14; quiz 415. doi: 10.1016/j.jaad.2013.09.010. |
| ［24］ | Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema ⁃ a systematic review and meta⁃analysis［J］. J Eur Acad Dermatol Venereol, 2007,21（5）:606⁃619. doi: 10.1111/j.1468⁃3083.2006.02023.x. |
| ［25］ | Wollenberg A, Barbarot S, Bieber T, et al. Consensus⁃based European guidelines for treatment of atopic eczema （atopic dermatitis） in adults and children: partⅡ［J］. J Eur Acad Dermatol Venereol, 2018,32（6）:850⁃878. doi: 10.1111/jdv.14888. |
| ［26］ | Altomare G, Ayala F, Bardazzi F, et al. Consensus on the use of cyclosporine in dermatological practice. Italian Consensus Conference［J］. G Ital Dermatol Venereol, 2014,149（5）:607⁃625. |
| ［27］ | Wollenberg A, Kinberger M, Arents B, et al. European guideline （EuroGuiDerm） on atopic eczema: partⅠ ⁃ systemic therapy［J］. J Eur Acad Dermatol Venereol, 2022,36（9）:1409⁃1431. doi: 10.1111/jdv.18345. |
| ［28］ | Tanei R. Atopic dermatitis in older adults: a review of treatment options［J］. Drugs Aging, 2020,37（3）:149⁃160. doi: 10.1007/s40266⁃020⁃00750⁃5. |
| ［29］ | Lee JH, Kim JE, Park GH, et al. Consensus update for systemic treatment of atopic dermatitis［J］. Ann Dermatol, 2021,33（6）:497⁃514. doi: 10.5021/ad.2021.33.6.497. |
| ［30］ | Drucker AM, Eyerich K, de Bruin⁃Weller MS, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement［J］. Br J Dermatol, 2018,178（3）:768⁃775. doi: 10.1111/bjd.15928. |
| ［31］ | Yu SH, Drucker AM, Lebwohl M, et al. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis［J］. J Am Acad Dermatol, 2018,78（4）:733⁃740.e11. doi: 10.1016/j.jaad.2017.09.074. |
| ［32］ | Wang FP, Tang XJ, Wei CQ, et al. Dupilumab treatment in moderate⁃to⁃severe atopic dermatitis: a systematic review and meta⁃analysis［J］. J Dermatol Sci, 2018,90（2）:190⁃198. doi: 10.1016/j.jdermsci.2018.01.016. |
| ［33］ | de Bruin⁃Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo⁃controlled, randomized phaseⅢ clinical trial （LIBERTY AD CAFÉ）［J］. Br J Dermatol, 2018,178（5）:1083⁃1101. doi: 10.1111/bjd.16156. |
| ［34］ | Matsutani M, Imai Y, Inoue Y, et al. Effectiveness and safety of tacrolimus ointment combined with dupilumab for patients with atopic dermatitis in real⁃world clinical practice［J］. J Dermatol, 2021,48（10）:1564⁃1568. doi: 10.1111/1346⁃8138.16039. |
| ［35］ | Rossi M, Rovati C, Arisi M, et al. A short cycle of narrow⁃band UVB phototherapy in the early phase of dupilumab therapy can provide a quicker improvement of severe atopic dermatitis［J］. Dermatology, 2021,237（3）:407⁃415. doi: 10.1159/000512456. |
| ［36］ | Beck LA, Deleuran M, Bissonnette R, et al. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open⁃Label Study of Adults with Moderate⁃to⁃Severe Atopic Dermatitis［J］. Am J Clin Dermatol, 2022,23（3）:393⁃408. doi: 10.1007/s40257⁃022⁃00685⁃0. |
| ［37］ | Neagu N, Dianzani C, Avallone G, et al. Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review［J］. J Eur Acad Dermatol Venereol, 2022,36（6）:820⁃835. doi: 10. 1111/jdv.17981. |
| ［38］ | Papp KA, Hong CH, Lansang MP, et al. Practical management of patients with atopic dermatitis on dupilumab［J］. Dermatol Ther （Heidelb）, 2021,11（5）:1805⁃1828. doi: 10.1007/s13555⁃021⁃00586⁃w. |
| ［39］ | Guex⁃Crosier Y, Di⁃Lucca J, Häusermann P, et al. Management of dupilumab⁃associated ocular surface diseases in atopic dermatitis patients［J］. Swiss Med Wkly, 2021,151:w30020. doi: 10.4414/SMW.2021.w30020. |
| ［40］ | 薛璐, 王惠平, 李燕. 度普利尤单抗治疗特应性皮炎引起"度普利尤单抗面部红斑"1例［J］. 中华皮肤科杂志, 2022,55（4）:337⁃338. doi: 10.35541/cjd.20210453. |
| ［41］ | Muzumdar S, Skudalski L, Sharp K, et al. Dupilumab facial redness/dupilumab facial dermatitis: a guide for clinicians［J］. Am J Clin Dermatol, 2022,23（1）:61⁃67. doi: 10.1007/s40257⁃021⁃00646⁃z. |
| ［42］ | Pope EM, Laageide L, Beck LA. Management of allergic skin disorders in pregnancy［J］. Immunol Allergy Clin North Am, 2023,43（1）:117⁃132. doi: 10.1016/j.iac.2022.05.012. |
| ［43］ | Koskeridis F, Evangelou E, Ntzani EE, et al. Treatment with dupilumab in patients with atopic dermatitis: systematic review and meta⁃analysis［J］. J Cutan Med Surg, 2022,26（6）:613⁃621. doi: 10.1177/12034754221130969. |
| ［44］ | Blauvelt A, Simpson EL, Tyring SK, et al. Dupilumab does not affect correlates of vaccine⁃induced immunity: a randomized, placebo⁃controlled trial in adults with moderate⁃to⁃severe atopic dermatitis［J］. J Am Acad Dermatol, 2019,80（1）:158⁃167.e1. doi: 10.1016/j.jaad.2018.07.048. |
| ［45］ | Zhao DJ, Huang LM, Xiao J, et al. Efficacy and safety of tralokinumab in the treatment of atopic dermatitis: a systematic review and meta⁃analysis of randomized controlled trials［J］. Medicine （Baltimore）, 2023,102（31）:e34516. doi: 10.1097/MD. 0000000000034516. |
| ［46］ | Simpson EL, Merola JF, Silverberg JI, et al. Safety of tralokinumab in adult patients with moderate⁃to⁃severe atopic dermatitis: pooled analysis of five randomized, double⁃blind, placebo⁃controlled phaseⅡ and phaseⅢ trials［J］. Br J Dermatol, 2022,187（6）:888⁃899. doi: 10.1111/bjd.21867. |
| ［47］ | Guttman⁃Yassky E, Teixeira HD, Simpson EL, et al. Once⁃daily upadacitinib versus placebo in adolescents and adults with moderate⁃to⁃severe atopic dermatitis （Measure Up 1 and Measure Up 2）: results from two replicate double⁃blind, randomised controlled phase 3 trials［J］. Lancet, 2021,397（10290）:2151⁃2168. doi: 10.1016/S0140⁃6736（21）00588⁃2. |
| ［48］ | Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow⁃up data from the measure up 1 and measure up 2 randomized clinical trials［J］. JAMA Dermatol, 2022,158（4）:404⁃413. doi: 10.1001/jamadermatol.2022.0029. |
| ［49］ | Meher BR, Mohanty RR, Padhy BM. Efficacy and safety of abrocitinib for the treatment of moderate⁃to⁃severe atopic dermatitis: a meta⁃analysis of randomized clinical trials［J］. J Dermatolog Treat, 2022,33（4）:2335⁃2343. doi: 10.1080/09546634. 2021.1961997. |
| ［50］ | Silverberg JI, de Bruin⁃Weller M, Bieber T, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: week 52 AD up study results［J］. J Allergy Clin Immunol, 2022,149（3）:977⁃987.e14. doi: 10.1016/j.jaci.2021.07.036. |
| ［51］ | Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate⁃to⁃severe atopic dermatitis from the phaseⅡ and phase Ⅲ clinical trial program［J］. Am J Clin Dermatol, 2021,22（5）:693⁃707. doi: 10. 1007/s40257⁃021⁃00618⁃3. |
| ［52］ | Gooderham MJ, Pink AE, Simpson EL, et al. Abrocitinib 100 mg once daily for moderate⁃to⁃severe atopic dermatitis: a review of efficacy and safety, and expert opinion on use in clinical practice［J］. Dermatol Ther （Heidelb）, 2023,13（9）:1893⁃1907. doi: 10. 1007/s13555⁃023⁃00948⁃6. |
| ［53］ | Narla S, Silverberg JI. The suitability of treating atopic dermatitis with Janus kinase inhibitors［J］. Expert Rev Clin Immunol, 2022,18（5）:439⁃459. doi: 10.1080/1744666X.2022. 2060822. |
| ［54］ | Clarke B, Yates M, Adas M, et al. The safety of JAK⁃1 inhibitors［J］. Rheumatology （Oxford）, 2021,60（Suppl 2）:ii24⁃ii30. doi: 10.1093/rheumatology/keaa895. |
| ［55］ | Blauvelt A, Silverberg JI, Lynde CW, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate⁃to⁃severe atopic dermatitis: results from the JAK1 atopic dermatitis efficacy and safety （JADE） REGIMEN phase 3 trial［J］. J Am Acad Dermatol, 2022,86（1）:104⁃112. doi: 10. 1016/j.jaad.2021.05.075. |
| ［56］ | Dodson J, Lio PA. Biologics and small molecule inhibitors: an update in therapies for allergic and immunologic skin diseases［J］. Curr Allergy Asthma Rep, 2022,22（12）:183⁃193. doi: 10. 1007/s11882⁃022⁃01047⁃w. |
| ［57］ | Liu L, Luo Y, Zhou M, et al. Tripterygium agents for the treatment of atopic eczema: a bayesian analysis of randomized controlled trials［J］. Phytomedicine, 2019,59:152914. doi: 10. 1016/j.phymed.2019.152914. |
| ［58］ | 周俐宏, 孙晓丽, 柳舟, 等. 口服复方甘草酸苷联合常规疗法治疗皮炎湿疹疗效及安全性的Meta分析［J］. 中国中西医结合皮肤性病学杂志, 2019,18（2）:97⁃102. doi: 10.3969/j.issn. 1672⁃0709.2019.02.001. |
| ［59］ | 树叶, 刘向宇, 罗鸯鸯, 等. 白芍总苷治疗儿童特应性皮炎的临床疗效［J］. 中国医师杂志, 2021,23（12）:1881⁃1883. doi: 10.3760/cma.j.cn431274⁃20210409⁃00401. |
| ［60］ | 中华医学会皮肤性病学分会免疫学组. 特应性皮炎的全程管理共识［J］. 中华皮肤科杂志, 2023,56（1）:5⁃15. doi: 10.35541/cjd.20220618. |
| ［61］ | Carrascosa JM, de la Cueva P, de Lucas R, et al. Patient journey in atopic dermatitis: the real⁃world scenario［J］. Dermatol Ther （Heidelb）, 2021,11（5）:1693⁃1705. doi: 10.1007/s13555⁃021⁃00592⁃y. |
| ［62］ | Boguniewicz M, Fonacier L, Guttman⁃Yassky E, et al. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape［J］. Ann Allergy Asthma Immunol, 2018,120（1）:10⁃22.e2. doi: 10.1016/j.anai.2017.10.039. |
| ［63］ | Wollenberg A, Thyssen JP, Bieber T, et al. A detailed look at the European Medicines Agency′s recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis［J］. J Eur Acad Dermatol Venereol, 2023,37（10）:2041⁃2046. doi: 10.1111/ jdv.19255. |
| ［64］ | De Bruin⁃Weller M, Biedermann T, Bissonnette R, et al. Treat⁃to⁃target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies［J］. Acta Derm Venereol, 2021,101（2）:adv00402. doi: 10.2340/00015555⁃3751. |
| ［65］ | 申晨, 陶娟. 特应性皮炎长期控制的评估演变与达标治疗［J］. 中华皮肤科杂志, 2022,55（5）:442⁃445. doi: 10.35541/cjd. 20210680. |
| ［66］ | Gori N, Chiricozzi A, Malvaso D, et al. Successful combination of systemic agents for the treatment of atopic dermatitis resistant to dupilumab therapy［J］. Dermatology, 2021,237（4）:535⁃541. doi: 10.1159/000512890. |
| ［67］ | de Wijs L, Thyssen JP, Vestergaard C, et al. An approach for the transition from systemic immunosuppressants to dupilumab［J］. J Eur Acad Dermatol Venereol, 2021,35（3）:e221⁃e223. doi: 10. 1111/jdv.16941. |
| ［68］ | Rick JW, Lio P, Atluri S, et al. Atopic dermatitis: a guide to transitioning to janus kinase inhibitors［J］. Dermatitis, 2023,34（4）:297⁃300. doi: 10.1097/DER.0000000000000950. |
| ［69］ | Saeki H, Akiyama M, Abe M, et al. English version of Japanese guidance for the use of oral Janus kinase （JAK） inhibitors in the treatments of atopic dermatitis［J］. J Dermatol, 2023,50（1）:e1⁃e19. doi: 10.1111/1346⁃8138.16635. |
| [1] | 中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会 中国中西医结合学会皮肤性病专业委员会 . [开放获取] 中国化学剥脱术临床应用专家共识（公众版2024版）[J]. 中华皮肤科杂志, 2024, 0(5): 20230620-e20230620. |
| [2] | 丁瑞 张卫亮 李静 陈羽佳 李珺莹. 度普利尤单抗治疗5例难治性内源性角化型手足部湿疹[J]. 中华皮肤科杂志, 2024, 0(4): 20230429-e20230429. |
| [3] | 宗杨永怡 马楚君 苏忠兰. 银屑病生物制剂治疗后湿疹化发生机制及应对策略[J]. 中华皮肤科杂志, 2024, 0(3): 20220578-e20220578. |
| [4] | 王煜坤 刘洁. 深度学习在非肿瘤性皮肤病中的应用进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220660-e20220660. |
| [5] | 陈星宇 姚煦. 中性粒细胞在炎症性皮肤病中的研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220865-e20220865. |
| [6] | 姚我 汪慧英. [开放获取] 拉那利尤单抗治疗遗传性血管性水肿临床试验的系统综述[J]. 中华皮肤科杂志, 2024, 0(3): 20230378-e20230378. |
| [7] | 陈竹 董丽萍 肖风丽. 基于代谢组学探究特应性疾病的研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220366-e20220366. |
| [8] | 中国“一带一路”皮肤病专病联盟分枝杆菌病研究联盟 中国麻风防治协会皮肤性病检验与诊断分会. 中国皮肤非结核分枝杆菌病诊治专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(2): 109-118. |
| [9] | 李吉 谢红付. 如何避免玫瑰痤疮的误诊[J]. 中华皮肤科杂志, 2024, 57(2): 119-122. |
| [10] | 赵迎 高翠娥 隋昕 宋志强. 基于高加索人单细胞转录组的炎症性树突状表皮细胞的免疫代谢研究[J]. 中华皮肤科杂志, 2024, 0(2): 20230550-e20230550. |
| [11] | 中国中西医结合学会皮肤性病专业委员会皮肤肿瘤学组 中国抗癌协会黑色素瘤专业委员会. [开放获取] 人干扰素α1b治疗黑色素瘤专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(1): 1-7. |
| [12] | 陈春里 闫思聿 王丹 高丽华 谭丽娜 唐四元 刘伟 曾金容 鲁建云. 酸化脂肪酸酯治疗特应性皮炎样模型小鼠的疗效及机制初探[J]. 中华皮肤科杂志, 2023, 56(9): 822-831. |
| [13] | 王珊 王星宇 舒虹 张斌 石航 杨欢 钱秋芳 马红艳 梁源 赵牧童 申春平 焦磊 田晶 汪洋 谷盈 孙婧 刘盈 李萍 王华 马琳. 克立硼罗软膏早期缓解儿童特应性皮炎临床症状及改善缓解期临床症状的多中心临床研究[J]. 中华皮肤科杂志, 2023, 56(9): 815-821. |
| [14] | 刘小扬 赵琰 蔡林 张建中. 银屑病患者白细胞介素17拮抗剂治疗后出现特应性皮炎样皮疹4例分析与文献回顾[J]. 中华皮肤科杂志, 2023, 56(9): 845-848. |
| [15] | 郭昊 刘辉 张丽 朱冠男 王平 姚志荣 高兴华 陈耀龙. 特应性皮炎诊疗指南（专科医生版本、全科医生版本和患者版本）计划书[J]. 中华皮肤科杂志, 2023, 56(9): 809-814. |
|
